The Putative Fidgetin Like Protein 2 pipeline drugs market research report outlays comprehensive information on the Putative Fidgetin Like Protein 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Putative Fidgetin Like Protein 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Dermatology, Central Nervous System, Ophthalmology, and Cardiovascular which include the indications Wounds, Burns, Spinal Cord Injury, Erectile Dysfunction, Ophthalmology, Keratitis, and Myocardial Infarction. It also reviews key players involved in Putative Fidgetin Like Protein 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Putative Fidgetin Like Protein 2 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in and Preclinical stages are and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Putative Fidgetin Like Protein 2 overview

Putative Fidgetin Like Protein 2 (FIGNL2) is a member of the AAA (ATPases Associated with diverse cellular Activities) family of ATPases. While its exact function and biological role are not fully characterized, FIGNL2 shares sequence homology with Fidgetin, a microtubule-severing AAA ATPase. The AAA family is known for its involvement in various cellular processes, often functioning as molecular machines that utilize the energy from ATP hydrolysis to exert mechanical force on their substrates. Fidgetin, the closely related counterpart, has been implicated in microtubule severing, a process crucial for cellular functions such as mitosis and intracellular transport.

For a complete picture of Putative Fidgetin Like Protein 2’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.